Menu -- Part 10: Retinal Reports from the 2007 AAO Meeting
1. Retina 2007 Subspecialty Meeting Presentations – Day One
● 2-Year results of the PrONTO Study (intravitreal injections of Lucentis with OCT diagnoses for guided further treatment);
● ANCHOR Update – Lucentis vs. PDT with Visudyne;
● Avastin vs. Lucentis – A discussion of the economic and moral dilemma of using approved Lucentis vs. off-label Avastin;
● Avastin’s Impact – Despite lack of clinical data;
New Treatments for AMD:
● VEGF Trap – discussions of the CLEAR-IT AMD 1 and CLEAR-It AMD 2 trials;
● Topical Therapies – discussions of various topical treatments
- TargeGen’s 801 kinase inhibitor
- CoMentis’ ATG2
- Ocucure’s OC-10X
- Othera’s OT-551
- Glaxo-Smith-Kline’s Pazopanib
● New Developments in posterior segment drug delivery – a discussion of potetial solid implants, such as Retisert and Vitrasert from Bausch & Lomb, and a subretinal implant system from SurModics called I-vation.
And, finally, an interview with Dr. Judah Folkman, the father of anti-angiogenic agents, and the keynote speaker for the opening session of the AAO Meeting.
2. Retina 2007 Subspecialty Meeting Presentations – Day Two
● A discussion of Dr. Susan Desmond-Hellmann’s (Genentech’s President, Product Development) presentation to the Retina 2007 assembly and her Q&A session;
● Sub-Retinal Implants for treating retinitis pigmentosa;
● Retinopathy of Prematurity – Anti-VEGF therapy is on the horizon;
● Spectral Domain Optical Coherence Tomography advances; and,
● New Non-Thermal Laser for Retinal Treatment – a brief discussion of the Ellex 2RT Therapy.
3. More Retinal Treatment News from the 2007 AAO – Day Three
● More from Retina 2007
- A Comparison of Lucentis vs. Avastin;
- An Update on the CATT Study;
- Additional information about the Ellex 2RT laser treatment.
● Retinal-related Information from the Main AAO Meeting
- The keynote address by Dr. Judah Folkman;
- An overview of intravitreal drugs for treating diabetic retinopathy; and,
- Intravitreal therapy for vein-occlusive disease.